Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Fixation stability and implication for multifocal electroretinography in patients with neovascular age-related macular degeneration after anti-VEGF treatment.

Pedersen KB, Sjølie AK, Vestergaard AH, Andréasson S, Møller F.

Graefes Arch Clin Exp Ophthalmol. 2016 Oct;254(10):1897-1908. Epub 2016 Apr 14.

PMID:
27080862
2.

Cardiovascular risk factors associated with age-related macular degeneration: the Tromsø Study.

Erke MG, Bertelsen G, Peto T, Sjølie AK, Lindekleiv H, Njølstad I.

Acta Ophthalmol. 2014 Nov;92(7):662-9. doi: 10.1111/aos.12346. Epub 2014 Jan 25.

3.

Sex differences in risk factors for retinopathy in non-diabetic men and women: the Tromsø Eye Study.

Bertelsen G, Peto T, Lindekleiv H, Schirmer H, Solbu MD, Toft I, Sjølie AK, Njølstad I.

Acta Ophthalmol. 2014 Jun;92(4):316-22. doi: 10.1111/aos.12199. Epub 2013 Jul 31.

4.

Retinal vascular calibre and response to light exposure and serial imaging.

von Hanno T, Sjølie AK, Mathiesen EB.

Acta Ophthalmol. 2014 Aug;92(5):444-8. doi: 10.1111/aos.12213. Epub 2013 Jul 4.

5.

Long-term associations between serum lipids and panretinal photocoagulation in type 1 diabetes.

Jørgensen JS, Jørgensen TM, Green A, Sjølie AK, Grauslund J.

Curr Eye Res. 2013 Aug;38(8):889-93. doi: 10.3109/02713683.2013.786094. Epub 2013 Apr 22.

PMID:
23806047
6.

Lactation, female hormones and age-related macular degeneration: the Tromsø Study.

Erke MG, Bertelsen G, Peto T, Sjølie AK, Lindekleiv H, Njølstad I.

Br J Ophthalmol. 2013 Aug;97(8):1036-9. doi: 10.1136/bjophthalmol-2012-302461. Epub 2013 Jun 12.

PMID:
23759439
7.

Is smoking a risk factor for proliferative diabetic retinopathy in type 1 diabetes?

Gaedt Thorlund M, Borg Madsen M, Green A, Sjølie AK, Grauslund J.

Ophthalmologica. 2013;230(1):50-4. doi: 10.1159/000350813. Epub 2013 Jun 7.

PMID:
23751972
8.

Long-term outcomes of photorefractive keratectomy for low to high myopia: 13 to 19 years of follow-up.

Vestergaard AH, Hjortdal JØ, Ivarsen A, Work K, Grauslund J, Sjølie AK.

J Refract Surg. 2013 May;29(5):312-9. doi: 10.3928/1081597X-20130415-02.

PMID:
23659229
9.

Retinal vascular calibres are significantly associated with cardiovascular risk factors: the Tromsø Eye Study.

von Hanno T, Bertelsen G, Sjølie AK, Mathiesen EB.

Acta Ophthalmol. 2014 Feb;92(1):40-6. doi: 10.1111/aos.12102. Epub 2013 Apr 29.

10.

Localized changes in retinal vessel caliber after focal/grid laser treatment in patients with diabetic macular edema: a measure of treatment response?

Lundberg K, Kawasaki R, Sjølie AK, Wong TY, Grauslund J.

Retina. 2013 Nov-Dec;33(10):2089-95. doi: 10.1097/IAE.0b013e3182891dda.

PMID:
23514802
11.

Tromsø eye study: prevalence and risk factors of diabetic retinopathy.

Bertelsen G, Peto T, Lindekleiv H, Schirmer H, Solbu MD, Toft I, Sjølie AK, Njølstad I.

Acta Ophthalmol. 2013 Dec;91(8):716-21. doi: 10.1111/j.1755-3768.2012.02542.x. Epub 2012 Sep 20.

12.

The Tromsø Eye Study: study design, methodology and results on visual acuity and refractive errors.

Bertelsen G, Erke MG, von Hanno T, Mathiesen EB, Peto T, Sjølie AK, Njølstad I.

Acta Ophthalmol. 2013 Nov;91(7):635-42. doi: 10.1111/j.1755-3768.2012.02511.x. Epub 2012 Sep 11.

13.

Associations between diabetic retinopathy and plasma levels of high-sensitive C-reactive protein or von Willebrand factor in long-term type 1 diabetic patients.

Laursen JV, Hoffmann SS, Green A, Nybo M, Sjølie AK, Grauslund J.

Curr Eye Res. 2013 Jan;38(1):174-9. doi: 10.3109/02713683.2012.713153. Epub 2012 Aug 20.

PMID:
22906118
14.

Prevalence of age-related macular degeneration in elderly Caucasians: the Tromsø Eye Study.

Erke MG, Bertelsen G, Peto T, Sjølie AK, Lindekleiv H, Njølstad I.

Ophthalmology. 2012 Sep;119(9):1737-43. doi: 10.1016/j.ophtha.2012.03.016. Epub 2012 May 16.

PMID:
22608479
15.

Prevalence of diabetic retinopathy in Norway: report from a screening study.

Kilstad HN, Sjølie AK, Gøransson L, Hapnes R, Henschien HJ, Alsbirk KE, Fossen K, Bertelsen G, Holstad G, Bergrem H.

Acta Ophthalmol. 2012 Nov;90(7):609-12. doi: 10.1111/j.1755-3768.2011.02160.x. Epub 2011 Sep 28.

16.

Proliferative retinopathy predicts nephropathy: a 25-year follow-up study of type 1 diabetic patients.

Karlberg C, Falk C, Green A, Sjølie AK, Grauslund J.

Acta Diabetol. 2012 Aug;49(4):263-8. doi: 10.1007/s00592-011-0304-y. Epub 2011 Jun 18.

PMID:
21688016
17.

[Endophthalmitis is an acute disease which threatens the vision].

Frydkjær-Olsen U, Sriskandarajah S, Sjølie AK.

Ugeskr Laeger. 2011 May 23;173(21):1493-6. Danish.

PMID:
21627911
18.

Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.

Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R, Aldington S, Chaturvedi N.

Diabet Med. 2011 Mar;28(3):345-51. doi: 10.1111/j.1464-5491.2010.03210.x.

PMID:
21309844
19.

Does renin-angiotensin system blockade have a role in preventing diabetic retinopathy? A clinical review.

Sjølie AK, Dodson P, Hobbs FR.

Int J Clin Pract. 2011 Feb;65(2):148-53. doi: 10.1111/j.1742-1241.2010.02552.x. Review.

PMID:
21235695
20.

Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials.

Porta M, Hainer JW, Jansson SO, Malm A, Bilous R, Chaturvedi N, Fuller JH, Klein R, Orchard T, Parving HH, Sjølie AK; DIRECT Study Group.

Diabetologia. 2011 Jun;54(6):1298-303. doi: 10.1007/s00125-010-2040-1. Epub 2011 Jan 12.

PMID:
21225239
21.

Angiotensin receptor blockade not related to history of dry eye symptoms and treatment in The Diabetic Retinopathy Candesartan Trials (DIRECT).

Moss SE, Klein R, Sjølie AK, Chaturvedi N, Malm AR, Fuller JH, Porta M; DIRECT Programme Study Group.

Acta Ophthalmol. 2011 Sep;89(6):e535-6. doi: 10.1111/j.1755-3768.2010.01992.x. Epub 2010 Aug 31. No abstract available.

22.

Electrophysiological assessment of retinal function during 6 months of bevacizumab treatment in neovascular age-related macular degeneration.

Pedersen KB, Møller F, Sjølie AK, Andréasson S.

Retina. 2010 Jul-Aug;30(7):1025-33. doi: 10.1097/IAE.0b013e3181cafc8f.

PMID:
20616681
23.

N-terminal pro brain natriuretic peptide reflects long-term complications in type 1 diabetes.

Grauslund J, Nybo M, Green A, Sjølie AK.

Scand J Clin Lab Invest. 2010 Oct;70(6):392-8. doi: 10.3109/00365513.2010.497869.

PMID:
20575653
24.

Does osteoprotegerin relate to micro- and macrovascular complications in long-term type 1 diabetes?

Grauslund J, Rasmussen LM, Green A, Sjølie AK.

Scand J Clin Lab Invest. 2010 Apr 19;70(3):188-93. doi: 10.3109/00365511003653599.

PMID:
20205614
25.

Retinal vascular fractals and microvascular and macrovascular complications in type 1 diabetes.

Grauslund J, Green A, Kawasaki R, Hodgson L, Sjølie AK, Wong TY.

Ophthalmology. 2010 Jul;117(7):1400-5. doi: 10.1016/j.ophtha.2009.10.047. Epub 2010 Feb 21.

PMID:
20176399
26.

Major diabetes-related vascular events do not improve glycaemic control in a population-based cohort of type 1 diabetic individuals.

Jørgensen TM, Grauslund J, Sjølie AK, Green A, Rasmussen LM, Nybo M.

Scand J Clin Lab Invest. 2009;69(7):748-51. doi: 10.3109/00365510903108410.

PMID:
19929717
27.

Cataract surgery in a population-based cohort of patients with type 1 diabetes: long-term incidence and risk factors.

Grauslund J, Green A, Sjølie AK.

Acta Ophthalmol. 2011 Feb;89(1):25-9. doi: 10.1111/j.1755-3768.2009.01619.x.

28.

Blindness in a 25-year follow-up of a population-based cohort of Danish type 1 diabetic patients.

Grauslund J, Green A, Sjølie AK.

Ophthalmology. 2009 Nov;116(11):2170-4. doi: 10.1016/j.ophtha.2009.04.043. Epub 2009 Sep 10.

PMID:
19744716
29.

Retinal arterioles have impaired reactivity to hyperoxia in type 1 diabetes.

Justesen BL, Mistry P, Chaturvedi N, Thom SA, Witt N, Köhler D, Hughes AD, Sjølie AK.

Acta Ophthalmol. 2010 Jun;88(4):453-7. doi: 10.1111/j.1755-3768.2009.01557.x. Epub 2009 Jul 21.

30.

Retinal vessel calibre and micro- and macrovascular complications in type 1 diabetes.

Grauslund J, Hodgson L, Kawasaki R, Green A, Sjølie AK, Wong TY.

Diabetologia. 2009 Oct;52(10):2213-7. doi: 10.1007/s00125-009-1459-8. Epub 2009 Jul 18.

PMID:
19618163
31.

Prevalence and 25 year incidence of proliferative retinopathy among Danish type 1 diabetic patients.

Grauslund J, Green A, Sjølie AK.

Diabetologia. 2009 Sep;52(9):1829-35. doi: 10.1007/s00125-009-1450-4. Epub 2009 Jul 12.

PMID:
19593541
32.

Risk factors for mortality and ischemic heart disease in patients with long-term type 1 diabetes.

Grauslund J, Jørgensen TM, Nybo M, Green A, Rasmussen LM, Sjølie AK.

J Diabetes Complications. 2010 Jul-Aug;24(4):223-8. doi: 10.1016/j.jdiacomp.2009.05.003. Epub 2009 Jul 3.

PMID:
19577486
33.

Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.

Bilous R, Chaturvedi N, Sjølie AK, Fuller J, Klein R, Orchard T, Porta M, Parving HH.

Ann Intern Med. 2009 Jul 7;151(1):11-20, W3-4. Epub 2009 May 18.

PMID:
19451554
34.

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients.

Pedersen KB, Sjølie AK, Møller F.

Acta Ophthalmol. 2009 Nov;87(7):714-9. doi: 10.1111/j.1755-3768.2008.01346.x. Epub 2008 Dec 16.

35.

Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial.

Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R, Chaturvedi N; DIRECT Programme Study Group.

Lancet. 2008 Oct 18;372(9647):1385-93. doi: 10.1016/S0140-6736(08)61411-7. Epub 2008 Sep 25.

36.

Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials.

Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R, Sjølie AK; DIRECT Programme Study Group.

Lancet. 2008 Oct 18;372(9647):1394-402. doi: 10.1016/S0140-6736(08)61412-9. Epub 2008 Sep 25.

PMID:
18823656
37.

Proliferative retinopathy and proteinuria predict mortality rate in type 1 diabetic patients from Fyn County, Denmark.

Grauslund J, Green A, Sjølie AK.

Diabetologia. 2008 Apr;51(4):583-8. doi: 10.1007/s00125-008-0953-8. Epub 2008 Feb 23.

PMID:
18297258
38.

Rationale and design of the AdRem study: evaluating the effects of blood pressure lowering and intensive glucose control on vascular retinal disorders in patients with type 2 diabetes mellitus.

Chaturvedi N, Bilous R, Sjolie AK, Klein R; DIRECT Programme Steering Committee.

Contemp Clin Trials. 2007 Nov;28(6):780. Epub 2007 Jun 26. No abstract available.

PMID:
17643353
39.

Prospects for angiotensin receptor blockers in diabetic retinopathy.

Sjølie AK.

Diabetes Res Clin Pract. 2007 May;76 Suppl 1:S31-9. Epub 2007 Feb 23. Review.

PMID:
17321627
40.

Fixation topography in normal test persons.

Møller F, Laursen ML, Sjølie AK.

Graefes Arch Clin Exp Ophthalmol. 2006 May;244(5):577-82. Epub 2005 Sep 17.

PMID:
16170533
41.

The contribution of microsaccades and drifts in the maintenance of binocular steady fixation.

Møller F, Laursen ML, Sjølie AK.

Graefes Arch Clin Exp Ophthalmol. 2006 Apr;244(4):465-71. Epub 2005 Sep 17.

PMID:
16170532
42.

[Antiangiogenesis therapy of age-related macular degeneration].

Sjølie AK, Mortensen KK, Hansen MH.

Ugeskr Laeger. 2005 Aug 29;167(35):3267. Danish. No abstract available.

PMID:
16138964
43.

The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics.

Sjølie AK, Porta M, Parving HH, Bilous R, Klein R; DIRECT Programme Study Group.

J Renin Angiotensin Aldosterone Syst. 2005 Mar;6(1):25-32.

PMID:
16088848
44.

Diabetic retinopathy is associated with mortality and cardiovascular disease incidence: the EURODIAB prospective complications study.

van Hecke MV, Dekker JM, Stehouwer CD, Polak BC, Fuller JH, Sjolie AK, Kofinis A, Rottiers R, Porta M, Chaturvedi N; EURODIAB prospective complications study.

Diabetes Care. 2005 Jun;28(6):1383-9.

PMID:
15920056
45.

Binocular fixation topography in patients with diabetic macular oedema: possible implications for photocoagulation therapy (3rd revision).

Møller F, Laursen ML, Sjølie AK.

Graefes Arch Clin Exp Ophthalmol. 2005 Sep;243(9):903-10. Epub 2005 Apr 15.

PMID:
15834607
46.

[Retinopathy of prematurity].

Sjølie AK, Jensen H.

Ugeskr Laeger. 2004 Nov 22;166(48):4345. Danish. No abstract available.

PMID:
15587622
47.

Medical management of diabetic retinopathy.

Sjølie AK, Møller F.

Diabet Med. 2004 Jul;21(7):666-72. Review.

PMID:
15209756
48.

The significance of the prepubertal diabetes duration for the development of retinopathy and nephropathy in patients with type 1 diabetes.

Olsen BS, Sjølie AK, Hougaard P, Johannesen J, Marinelli K, Jacobsen BB, Mortensen HB; Danish Study Group of Diabetes in Childhood.

J Diabetes Complications. 2004 May-Jun;18(3):160-4.

PMID:
15145327
49.

The prevalence and incidence of visual impairment in people of age 20-59 years in industrialized countries: a review.

Rothe Nissen K, Sjølie AK, Jensen H, Borch-Johnsen K, Rosenberg T.

Ophthalmic Epidemiol. 2003 Oct;10(4):279-91. Review.

PMID:
14628970
50.

[Diabetic retinopathy--new challenges].

Larsen JN, Sjølie AK.

Ugeskr Laeger. 2003 Jul 21;165(30):2951. Danish. No abstract available.

PMID:
12926195

Supplemental Content

Loading ...
Support Center